Compare Eli Lilly And Co (LLY) vs Nvidia Corp (NVDA) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

NVIDIA (NVDA) trades at $205.95, up 1.55% on the day, with a neutral technical signal. The stock exhibits exceptional fundamental strength, with revenue surging to $130.50B in 2025 and net income margin reaching 62.97%. Recent quarterly earnings have consistently exceeded expectations, and analyst consensus remains strongly bullish with a $325.86 price target, though some institutional investors have recently trimmed positions.

The outlook is supported by dominant positioning in AI infrastructure, with revenue growth expected to continue. Key risks include peak AI spending concerns, intensifying competition, and high valuation multiples. The stock's performance is closely tied to the sustainability of the AI investment cycle and its ability to maintain technological leadership.